Curida AS In Norway is a partner in Regenics BIA project. Curida’s development expertise covers the full service for the development of nasal and inhalation drug products (OINDP). The cGMP compliant laboratory service includes the extensive performance characterisation studies for nasal and inhalation drug products (OINDP) and other dosage forms provided with a delivery device, such as ophthalmic or topical products.

Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology, Nasal Spray and Bottles. Within these areas, Curida also offers manufacturing of investigational products for clinical studies. Curida’s experience and competency includes handling of controlled drugs.
In addition to full-scale manufacturing, Curida offers small-scale production for samples and stability testing. 


Contact information:

Oslo Cancer Cluster
Ullernchausseen 66
0379 Oslo



Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.